MX389468B - Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña - Google Patents

Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña

Info

Publication number
MX389468B
MX389468B MX2019006844A MX2019006844A MX389468B MX 389468 B MX389468 B MX 389468B MX 2019006844 A MX2019006844 A MX 2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A MX 389468 B MX389468 B MX 389468B
Authority
MX
Mexico
Prior art keywords
hydroxybutyrates
glyceryl
control
migraine symptoms
migraine
Prior art date
Application number
MX2019006844A
Other languages
English (en)
Other versions
MX2019006844A (es
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MX2019006844A publication Critical patent/MX2019006844A/es
Publication of MX389468B publication Critical patent/MX389468B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método de control de la reducción y/o la profilaxis y/o el control de los síntomas de migraña mediante el uso de glicéridos de 3-hidroxibutato.
MX2019006844A 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña MX389468B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
MX2019006844A MX2019006844A (es) 2019-08-16
MX389468B true MX389468B (es) 2025-03-20

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006844A MX389468B (es) 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña

Country Status (13)

Country Link
US (2) US20180177753A1 (es)
EP (1) EP3558458B1 (es)
JP (1) JP7108320B2 (es)
KR (1) KR102390608B1 (es)
CN (1) CN110167637B (es)
BR (1) BR112019012431A2 (es)
CA (1) CA3046350C (es)
ES (1) ES2962879T3 (es)
IL (1) IL267540B (es)
MX (1) MX389468B (es)
MY (1) MY190308A (es)
PT (1) PT3558458T (es)
WO (1) WO2018118369A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
PL3558280T3 (pl) 2016-12-21 2023-10-16 Universitäts-Kinderspital Beider Basel Zapobieganie i leczenie migreny
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2020147980A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von struktureinheiten auf basis von glyceriden von hydroxycarbonsäuren enthaltenden lipiden
US12258609B2 (en) 2019-01-17 2025-03-25 Ketolipix Therapeutics Gmbh Method for producing glycerides of hydroxycarboxylic acids
MX2021010945A (es) * 2019-03-14 2021-10-13 Neuroenergy Ventures Inc Formula que enmascara el sabor para compuestos de cuerpos cetonicos.
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
JP7403861B2 (ja) * 2019-05-30 2023-12-25 ニューロエナジー ベンチャーズ、インコーポレイテッド グリセリルトリス（β－ヒドロキシ酪酸）及びニューロン一過性虚血性発作
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
EP4412987A1 (en) 2021-11-26 2024-08-14 Arxada AG Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US20240299548A1 (en) * 2022-01-18 2024-09-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2024083889A1 (en) 2022-10-18 2024-04-25 Arxada Ag Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
PT2001293T (pt) 2006-04-03 2018-11-28 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
BRPI1005372A2 (pt) * 2009-01-24 2018-03-06 Phytopharm Plc metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas
WO2012154837A2 (en) 2011-05-09 2012-11-15 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
PE20151949A1 (es) * 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2015156865A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
EP3322427A4 (en) 2015-07-10 2019-07-17 Cognate Nutritionals, Inc. MIGRAINE PROPHYLAXIS AND MITIGATION USING MEDIUM CHAIN TRIGLYCERIDES, KETONE ESTERS, AND OTHER KETOGENIC SOURCES
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
EP3509580A4 (en) 2016-09-12 2020-05-13 University of South Florida NEUROREGENERATION IMPROVED BY KETONE
PL3558280T3 (pl) 2016-12-21 2023-10-16 Universitäts-Kinderspital Beider Basel Zapobieganie i leczenie migreny

Also Published As

Publication number Publication date
CN110167637A (zh) 2019-08-23
CA3046350C (en) 2022-08-16
IL267540A (en) 2019-08-29
IL267540B (en) 2022-07-01
MY190308A (en) 2022-04-13
CA3046350A1 (en) 2018-06-28
JP2020502250A (ja) 2020-01-23
EP3558458A1 (en) 2019-10-30
PT3558458T (pt) 2023-11-27
JP7108320B2 (ja) 2022-07-28
KR102390608B1 (ko) 2022-04-25
MX2019006844A (es) 2019-08-16
EP3558458B1 (en) 2023-10-18
WO2018118369A1 (en) 2018-06-28
ES2962879T3 (es) 2024-03-21
KR20190099465A (ko) 2019-08-27
US10792269B2 (en) 2020-10-06
US20180177753A1 (en) 2018-06-28
CN110167637B (zh) 2023-03-14
BR112019012431A2 (pt) 2020-04-14
US20190117612A1 (en) 2019-04-25
EP3558458A4 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
MX389468B (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña
IL261627B (en) A method and system for optimizing and predicting demand response
IL263680A (en) Combination therapies
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CL2019000505A1 (es) Unidad de tratamiento para tratamiento de hilo en línea.
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2018007123A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo.
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112019020338A8 (pt) Composição para produção de tagatose, e, método de produção de tagatose
MX2020009939A (es) Metodos para tratar el sindrome de prader-willi.
MX2018013660A (es) Seleccion de cepas bacterianas utiles en el tratamiento de la alergia.
PL3683760T3 (pl) Sposób sterowania systemem dostaw energii
EP3766155C0 (en) REDUNDANT POWER SUPPLY SYSTEM
HUE037945T2 (hu) Eljárás mozgási rendellenességek kezelésére befiradollal
UY37152A (es) Mutante de corynebacterium glutamicum que produce l-histidina y método para producir l-histidina utilizando el mismo